Bayer (BAYRY) Upgraded at Zacks Investment Research

Bayer (OTCMKTS:BAYRY) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Wednesday. The firm presently has a $36.00 price target on the stock. Zacks Investment Research‘s price objective points to a potential upside of 13.21% from the company’s current price.

According to Zacks, “As part of its strategy to complete the planned acquisition of Monsanto, Bayer inked an agreement to sell selected Crop Science businesses to BASF. With this agreement, the company will actively address the authorities’ possible concerns regarding the planned acquisition of Monsanto and facilitate a successful closing of the transaction by early 2018. The combined enterprise will be able to bring innovations to the market faster and provide its customers with better solutions. However, the company is facing generic competition for many of its products including the Yaz franchise (oral contraceptives). The generics of key drugs will negatively impact revenues. Yet, Bayer’s shares have outperformed the industry year to date. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters.”

BAYRY has been the subject of several other research reports. ValuEngine upgraded shares of Bayer from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. BNP Paribas upgraded shares of Bayer from a “neutral” rating to an “outperform” rating in a report on Monday, September 25th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $36.00.

Shares of Bayer (OTCMKTS:BAYRY) traded down $0.16 during mid-day trading on Wednesday, hitting $31.80. 355,573 shares of the company were exchanged, compared to its average volume of 426,802. The company has a quick ratio of 1.01, a current ratio of 1.51 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $105,440.00, a PE ratio of 27.89, a P/E/G ratio of 1.95 and a beta of 1.14. Bayer has a 52-week low of $26.86 and a 52-week high of $35.41.

Bayer (OTCMKTS:BAYRY) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.14. Bayer had a net margin of 10.88% and a return on equity of 18.53%. equities analysts forecast that Bayer will post 2.27 earnings per share for the current fiscal year.

WARNING: “Bayer (BAYRY) Upgraded at Zacks Investment Research” was originally published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/17/bayer-bayry-upgraded-at-zacks-investment-research.html.

About Bayer

Bayer AG is a life science company. The Company’s segments are Pharmaceuticals, Consumer Health, Animal Health and Covestro. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology.

Get a free copy of the Zacks research report on Bayer (BAYRY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply